CAR T Cell Adds Scorpion Venom to Tackle Tumor Heterogeneity

A newly engineered CAR T cell that incorporates a peptide isolated from the venom of the deathstalker scorpion has broad brain tumor–binding capabilities that will be investigated in an upcoming clinical trial.